Analyst Rating Update on Chimerix (CMRX)

Chimerix (NASDAQ:CMRX) has an average broker rating of 2.92, which is interpreted as a Hold, as rated by 9 equity analysts. Nonetheless, 1 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 7 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold. 1 brokerage firm advices Strong Sell on the share due to lack of confidence about the future of the company.

Chimerix (NASDAQ:CMRX) has been rated by 8 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $15 and the lowest price target forecast is $5. The average forecast of all the analysts is $8.38 and the expected standard deviation is $3.46.

Company shares have received an average consensus rating of Hold for the current week

Chimerix (NASDAQ:CMRX): stock turned positive on Tuesday. Though the stock opened at $3.67, the bulls momentum made the stock top out at $3.84 level for the day. The stock recorded a low of $3.62 and closed the trading day at $3.81, in the green by 7.02%. The total traded volume for the day was 1,439,690. The stock had closed at $3.56 in the previous days trading.

In an insider trading activity, Mario Ernest, director of Chimerix Inc, executed a transaction worth $45,300 on May 13, 2016. A total of 10,000 shares were purchased at an average price of $4.53. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.

Chimerix, Inc. a biopharmaceutical company dedicated to discovering, developing and commercializing oral antivirals. The Companys lipid conjugate technology has developed its lead compound, brincidofovir (BCV, CMX001), which is in Phase III clinical development. It is clinical-stage nucleotide analog lipid-conjugate which has demonstrated potent antiviral activity and safety in convenient, orally administered dosing regimens. In addition, it has an active discovery program focusing on viral targets. CMX157, is its second clinical-stage nucleotide analog, uses the same lipid technology as brincidofovir to deliver high intracellular concentrations of the potent antiviral drug, tenofovir. Tenofovir, marketed under the brand name Viread and in multiple fixed-dose combinations, is used for the treatment of human immunodeficiency virus (HIV) and hepatitis B virus (HBV) infection. It has discovered, developed and selected a clinical candidate, CMX669, for BK virus and cytomegalovirus (CMV).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.